The Technical Analyst
Quanterix Corp [QTRX]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Quanterix Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.25% $15.79
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 601.02 mill |
| EPS: | -0.860 |
| P/E: | -18.36 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 38.06 mill |
| Avg Daily Volume: | 0.352 mill |
| RATING 2024-04-18 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -18.36 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.08x |
| Company: PE -18.36 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 14.32 - 17.26 ( +/- 9.30%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Toloue Masoud | Sell | 1 120 | Common Stock |
| 2024-04-01 | Donnelly William P | Buy | 525 | Common Stock |
| 2024-04-01 | Meister Paul M | Buy | 630 | Common Stock |
| 2024-04-01 | Hlavinka Sarah E. | Buy | 630 | Common Stock |
| 2024-04-01 | Olson Laurie J | Buy | 1 000 | Common Stock |
| INSIDER POWER |
|---|
| 90.60 |
| Last 96 transactions |
| Buy: 1 249 474 | Sell: 53 877 |
Forecast:
16:00 - $15.79
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $15.79
Forecast 2: 16:00 - $15.79
Forecast 3: 16:00 - $15.79
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $15.79 (0.25% ) |
| Volume | 0.332 mill |
| Avg. Vol. | 0.352 mill |
| % of Avg. Vol | 94.33 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For QTRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $24.19 | N/A | Active |
|---|
QTRX
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Latest Press Releases
2024-03-21 17:30:00 - Press Release
Quanterix Outlines Partner Path With Labs To Expedite Building Global Alzheimer's Disease Testing Infrastructure
Billerica, mass.--(business wire)--quanterix corporation (nasdaq: qtrx), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering tau based research and diagnostic testing services. quanterix has secured over thirty u.s. patents protecting our innovative ultra-sensitive research products and high-definition diagnostics, and we continue to secure additional patent protection, both.
2024-03-04 09:00:00 - Press Release
Quanterix Granted Breakthrough Device Designation From U.s. Fda For Blood-based P-tau 217 Test For Alzheimer's Disease
Billerica, mass.--(business wire)--quanterix corporation (nasdaq: qtrx), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its simoa® phospho-tau 217 (p-tau 217) blood test has been granted breakthrough device designation by the u.s. food and drug administration (fda) as an aid in diagnostic evaluation of alzheimer's disease (ad). the fda's breakthrough device designation is granted to products that have the potential to offer more eff.
2024-02-29 16:00:00 - Press Release
Quanterix Releases Operating Results For Fourth Quarter And Full Year 2023
Billerica, mass.--(business wire)--quanterix corporation (nasdaq: qtrx), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended december 31, 2023. “the fourth quarter marked the successful completion of our corporate transformation. we now have a strong, scalable foundation for growth and innovation,” said masoud toloue, president and chief executive officer of quanterix. “our research b.
2024-02-26 18:58:00 - Press Release
Quanterix Reschedules Q4 And Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
Billerica, mass.--(business wire)--quanterix corporation (nasdaq: qtrx) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended december 31, 2023 and the associated conference call in order to more closely align the release of such results with the filing of its annual report on form 10-k for the year ended december 31, 2023, the deadline for which is february 29, 2024. the investor call will now be held on thursday, february 29, 2024.
2024-02-26 09:00:00 - Press Release
Quanterix Announces First Collaborations With Five Health Networks To Aid The Diagnosis And Clinical Management Of Individuals With Alzheimer's Disease
Billerica, mass.--(business wire)--quanterix corporation (nasdaq: qtrx), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced its first collaborations with health systems in pursuit of their shared goal to improve and simplify alzheimer's disease (ad) diagnosis. these relationships further the company's goal to build the global infrastructure necessary for ad testing by expanding clinical access to quanterix's leading blood biomarker assays. c.
Latest News
2024-03-06 10:51:15 - Zacks Investment Research
Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
2024-02-29 18:11:13 - Zacks Investment Research
Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.50 per share a year ago.
2024-02-27 11:06:07 - Zacks Investment Research
Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
2024-02-26 18:58:00 - Business Wire
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release of such results with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023, the deadline for which is February 29, 2024. The investor call will now be held on Thursday, February 29, 2024.
2024-02-23 16:30:00 - Business Wire
Quanterix to Present at Cowen's 44th Annual Health Care Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Cowen's 44th Annual Health Care Conference. Quanterix's session will take place on Monday, March 4, 2024, at 12:50 p.m. EST and will be made available to attendees and, via webcast, the general public. In addition to the session, Quanterix will also host one-on-one me.
2024-02-16 16:00:00 - Business Wire
Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results. The call will begin at 8:30 AM Eastern Time. It will be hosted by Masoud Toloue, the Company's President and Chief Executive Officer, and Vandana Sriram, the Company's Chief Financial Offi.
2023-12-04 13:32:37 - Zacks Investment Research
Here's Why Quanterix Corporation (QTRX) is a Great Momentum Stock to Buy
Does Quanterix Corporation (QTRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
2023-11-13 11:17:51 - Zacks Investment Research
Wall Street Analysts See a 54.88% Upside in Quanterix Corporation (QTRX): Can the Stock Really Move This High?
The mean of analysts' price targets for Quanterix Corporation (QTRX) points to a 54.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2023-11-07 15:15:23 - Seeking Alpha
Quanterix Corporation (QTRX) Q3 2023 Earnings Call Transcript
Quanterix Corporation (NASDAQ:QTRX ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Ed Joyce - VP, IR Masoud Toloue - President and CEO Vandana Sriram - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Jake Allen - Goldman Sachs Dan Brennan - Cowen Puneet Souda - Leerink Partners Operator Good day and thank you for standing by. Welcome to the Quanterix Corporation Q3 2023 Earnings Call.
2023-11-06 17:30:45 - InvestorPlace
7 Stocks to Buy if You Anticipate a Hot November
While enough evidence exists that justify a pessimistic view of the market – in particular, high inflation and high borrowing costs – it's also possible that a hot November could rejuvenate previously embattled stocks to buy. And that's not an entirely speculative proposition.